Company profile
CAPRICOR THERAPEUTICS, INC.
NASDAQ:CAPRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DERAMIOCEL | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03406780 | phase2 | completed | 2018-04-04 | 2020-03-10 | Capricor Inc. | A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy |
| NCT05126758 | phase3 | active_not_recruiting | 2022-06-22 | 2025-06-18 | Capricor Inc. | A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy |
| NCT01458405 | phase1_2 | terminated | 2012-11-13 | 2017-07-03 | Capricor Inc. | Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration |
| NCT02293603 | phase1 | unknown | 2014-11-01 | 2015-05-01 | Capricor Inc. | Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC) |
| NCT02485938 | phase2 | completed | 2016-01-07 | 2017-09-14 | Capricor Inc. | HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) |
FDA applications (0)
No records yet.